

## COMPLETION OF RETAIL ENTITLEMENT OFFER

- **PYC is raising \$146m<sup>1</sup> through an Accelerated Non-Renounceable Entitlement Offer (ANREO or Entitlement Offer) announced to the ASX on 17 February 2025<sup>1</sup>**
- **The institutional component of the Entitlement Offer raised ~\$91 million<sup>1</sup> and the retail component of the Entitlement Offer has been fully underwritten<sup>2</sup>**
- **PYC today advises that ~\$9.3m has been raised through completion of the retail component of the Entitlement Offer bringing the total funds raised to date to ~\$100m with the balance of the ~\$146m to be raised through the underwriting facility<sup>3</sup>**
- **Upon completion of the Entitlement Offer, PYC will be funded to progress its entire pipeline of four first-in-class drug candidates with disease-modifying potential through major human data read-outs<sup>4</sup>**

### PERTH, Australia – 18 March 2025

PYC Therapeutics Limited (ASX:PYC) (**PYC** or the **Company**) today announces that it has raised \$9.3m<sup>1</sup> through completion of the retail component of the Entitlement Offer announced to the ASX on 17 February 2025. The Retail component of the Entitlement Offer was fully underwritten and the balance of the funds contemplated will be raised through settlement of the Underwriting Agreement on or before 7 April 2025<sup>5</sup>.

The total ~\$146m to be raised through completion of the Offer will see PYC funded to deliver multiple human efficacy read-outs within its pipeline of first-in-class drugs with disease-modifying potential in areas of major unmet patient need<sup>6</sup>.

### Retail Offer Results

43,667,849 New Shares were offered to eligible retail shareholders under the Retail component of the Entitlement Offer at \$1.25 per share to raise a total of up to \$54.6<sup>1</sup> million. Valid applications from eligible retail shareholders were received and accepted for

<sup>1</sup> See ASX announcement of 17 February 2025

<sup>2</sup> See ASX announcement of 17 February for details of the Underwriting Agreement

<sup>3</sup> See ASX announcement of 17 February for details of the Underwriting Agreement

<sup>4</sup> Subject to the risks and uncertainties outlined in the Offer documentation

<sup>5</sup> See the description of the \$70m underwriting facility described in the Investor Presentation released to the ASX on 17 February 2025 and subject to the risks set out in that document

<sup>6</sup> Subject to the risks and uncertainties outlined in the Company's ASX filings of 17 February 2025

7,464,090 New Shares raising \$9.3 million before costs<sup>7</sup>. The balance of 36.2m New Shares contemplated under the Entitlement Offer will be issued under the Underwriting Agreement with settlement expected to occur on or before 7 April 2025<sup>8</sup>.

New Shares subscribed for under the Retail Entitlement Offer are expected to be issued on Friday 21 March 2025 and commence trading on the ASX on Monday 24 March 2025.

### **About PYC Therapeutics**

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**<sup>9</sup>.

For more information, visit [pyctx.com](http://pyctx.com), or follow us on LinkedIn and Twitter.

### **Forward looking statements**

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

*This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited*

### **CONTACTS:**

**INVESTORS and MEDIA**  
[investor@pyctx.com](mailto:investor@pyctx.com)

<sup>7</sup> Includes additional 0.2 million New Shares were subscribed for by the Foreign Holder Nominee

<sup>8</sup> See the description of the \$70m underwriting facility described in the Investor Presentation released to the ASX on 17 February 2025 and subject to the risks set out in that document

<sup>9</sup> Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank  
<https://doi.org/10.1101/2020.11.02.20222232>